Poolbeg Pharma PLC (POLBF) Q4 2025 Earnings Call Transcript
Poolbeg Pharma PLC held its Q4 2025 earnings call on April 28, 2026, presenting full-year results and an update on its clinical-stage drug candidate POLB 001. CEO Jeremy Skillington and Principal Scientist Liam Tremble discussed the company's progress and ongoing clinical trials. The presentation highlighted the potential of POLB 001 to impact cancer treatment, though no definitive efficacy or safety data were detailed in the provided excerpt.
- ▪Poolbeg Pharma PLC is a clinical-stage company developing the drug candidate POLB 001.
- ▪The Q4 2025 earnings call took place on April 28, 2026, and included a presentation by CEO Jeremy Skillington and Principal Scientist Liam Tremble.
- ▪The company believes POLB 001 has the potential to transform outcomes for cancer patients.
- ▪Full-year results were announced prior to the investor presentation.
- ▪The call focused on updates regarding the clinical development of POLB 001.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4897642-poolbeg-pharma-plc-polbf-q4-2025-earnings-call-transcript"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at All Articles on Seeking Alpha.
Discussion
0 commentsMore from All Articles on Seeking Alpha
